シクリンD1アブレーションによる乳がんに対する特殊な保護
Q Yu1, Y Geng, P Sicinski
1Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nature
|June 29, 2001
まとめ
サイクリンD1が欠けていたマウスは,neuとrasの腫瘍遺伝子が駆動する乳がんに抵抗したが,他の腫瘍遺伝子は抵抗しなかった. これは,サイクリンD1がニューラル誘発性乳腺腫瘍に不可欠であることを示唆し,潜在的な標的療法を示唆しています.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- 乳がんは女性の主要な悪性腫瘍です.
- 細胞循環の調節体であるサイクリンD1の過剰発現は,乳がんにおいて一般的です.
- サイクリンD1は,細胞サイクル進行において重要な役割を果たします.
研究 の 目的:
- 乳がんの発症におけるサイクリンD1の役割を調査する.
- サイクリンD1の欠乏が腫瘍遺伝子誘発性乳腺腫瘍に対する耐性を与えるかどうかを判断する.
- 特定の腫瘍発生経路がサイクリンD1.1に依存しているかを調査する.
主な方法:
- 遺伝子ターゲティングは,サイクリンD1欠乏したマウスを生成するために使用されました.
- 乳腺腫瘍は,neuとrasの腫瘍遺伝子を用いて誘発された.
- 他の腫瘍性経路 (c-myc,Wnt-1) に対する感受性は,サイクリンD1欠乏したマウスで評価された.
主要な成果:
- サイクリンD1欠乏したマウスは,neuおよびras腫瘍遺伝子が誘発した乳がんに耐性を示した.
- サイクリンD1欠乏マウスの乳腺上皮は,c-mycまたはWnt-1によって駆動される腫瘍性経路に対して敏感であり続けた.
- Neu-Ras経路は,乳腺上皮細胞の変容のためにサイクリンD1に依存することが判明しました.
結論:
- サイクリンD1は,ニューラス経路経由で乳腺上皮細胞の悪性変異に不可欠である.
- サイクリンD1を標的にすることは,活性化されたニューラス経路を有するヒト乳がんに対する特定の治療戦略を提供することができる.
- この発見は,腫瘍形成におけるサイクリンD1の経路特異的な役割を強調している.
さらに関連する動画
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
08:16X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models
Published on: September 12, 2025
関連する概念動画
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...